SDZ 208-912
chemical compound
SDZ 208-912 is an experimental antipsychotic of the ergoline family which was under development for the treatment of psychotic disorders but was never marketed. Its route of administration is unknown.
The drug shows high affinity for the dopamine D2 receptor, α1-adrenergic receptor, and serotonin 5-HT1A receptor, as well as somewhat lower affinity for the dopamine D1 receptor, α2-adrenergic receptor, and serotonin 5-HT2 receptor. It acts as a weak partial agonist of the dopamine D2 and D3 receptors. SDZ 208-912 inhibits dextroamphetamine-induced hyperlocomotion and apomorphine-induced compulsive gnawing in rodents. It has a low or negligible propensity for causing catalepsy. The drug strongly suppresses prolactin levels and produces antiparkinsonian-like effects in rodents.
SDZ 208-912 was first described in the scientific literature by 1988. It was under development by Novartis. The drug reached phase 2 clinical trials for psychotic disorders in the United States and European Union prior to the discontinuation of its development in 1998.
This brief starts where responsible research should: with the source description of “SDZ 208-912” as chemical compound. Everything that follows is an evidence route, not borrowed authority.
Why this record matters
The subject matters to the science & nature register because the source frames it as chemical compound. Its deeper value depends on whether names, dates, institutions and citations support that framing.
Stable identifiers, scientific names and standards terminology offer the best bridge between this overview and specialist evidence. The source revision retrieved here is dated Aug 22, 2026. The linked authority identifier is Q27263239. None of the 0 selected statements returned an explicit reference. The first chronological checks are 1988 and 1998.
A general summary may omit uncertainty, sample limits or methodological disagreement that is explicit in the technical record. The lead is largely declarative, so disagreement and counter-evidence require a deliberate search beyond the opening account. Authority statements aid reconciliation but still require their own references, qualifiers and ranks to be checked.
How to read it
Check terminology, classification and the date of the cited evidence. Scientific names and technical consensus can change while older records retain historical value.
- Current terminology
- Classification context
- Finding cited technical literature
Primary datasets, specimen catalogues, standards bodies and the most recent peer-reviewed literature.
Three-step research path
- Establish the record: confirm the title “SDZ 208-912”, its source revision and the description used here.
- Expand the search: follow SDZ 208-912 primary sources, SDZ 208-912 archive and 208-912 research across catalogues and specialist indexes.
- Test the account: compare the strongest cited source with the responsible institution’s current record and note any disagreement.
Questions for further research
- Which source most directly establishes the central claim about “SDZ 208-912”?
- Is the terminology current, historical or disputed?
- Which observation, specimen, dataset or publication supports the account?
Search terms from this dossier
This entry incorporates text from “SDZ 208-912” on English Wikipedia. Contributors are listed in the page history. Text is available under the Creative Commons Attribution-ShareAlike 4.0 License. Selected authority identifiers and statements are retrieved from Wikidata under CC0; their references and qualifiers remain part of the verification path.